Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 3001 to 3050 of 3765 results for treatment

  1. What is the safety and efficacy of botulinum toxin compared with (a) usual care, (b) antimuscarinics and (c) augmentation cystoplasty in people with primary cerebral conditions with lower urinary tract dysfunction?

    include heterogeneous groups of patients. Potential benefits of successful treatment in cerebral disease may include the avoidance of...

  2. Delirium in long-term care: How common is delirium and what are its adverse outcomes in people in long-term care?

    study would also inform cost-effectiveness analyses for the prevention and treatment of delirium. Source guidance details Comes from...

  3. Drug allergy (QS97)

    This quality standard covers diagnosing and managing drug allergy in adults, young people and children. It describes high-quality care in priority areas for improvement.

  4. Chief executive's end of year message

    Dr Sam Roberts, chief executive at NICE, looks back at NICE's achievements over the past year and discusses our priorities for 2023.

  5. Are psychological interventions effective for treating moderate to severe anxiety disorders (including obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder and social anxiety disorder) in pregnancy?

    interventions (for example, mode of delivery, duration, content, and intensity of treatment) that are needed for use in pregnancy - the...

  6. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (TA251)

    This guidance has been updated and replaced by NICE technology appraisal guidance 426.

  7. Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease (TA558)

    This guidance has been updated and replaced by NICE technology appraisal guidance 684.

  8. Ganaxolone for adjunctive treatment of epilepsy associated with tuberous sclerosis complex with CDKL5 deficiency disorder [TSID12126]

    In development Reference number: GID-TA11697 Expected publication date: TBC

  9. Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer [ID6472]

    In development Reference number: GID-TA11589 Expected publication date: TBC

  10. SecurAcath for securing percutaneous catheters (HTG440)

    Evidence-based recommendations on SecurAcath for securing percutaneous catheters.

  11. Flu vaccination: increasing uptake (NG103)

    This guideline covers how to increase uptake of the free flu vaccination among people who are eligible. It describes ways to increase awareness and how to use all opportunities in primary and secondary care to identify people who should be encouraged to have the vaccination.

  12. Is structured clinical management for moderate to severe personality disorders in pregnancy and the postnatal period effective at improving outcomes for women and their babies?

    disorder may present problems for engagement even in those motivated to seek treatment. Structured clinical management is a...

  13. Radiofrequency denervation:- What is the clinical and cost effectiveness of radiofrequency denervation for chronic low back pain in the long term?

    the outcomes and duration of these outcomes are similar to the initial treatment. If repeated radiofrequency denervation is to be...

  14. Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck (TA172)

    This guidance has been updated and replaced by NICE technology appraisal guidance 473.

  15. Seroprevalence of Lyme disease-specific antibodies and other tick-borne infections in the UK population:- What is the current seroprevalence of Lyme disease-specific antibodies and other tick-borne infections in people in the UK?

    to confirm or refute this. Better evidence may improve diagnostic and treatment decisions. Source guidance details Comes from guidance

  16. Servo-n with Neurally Adjusted Ventilatory Assist (NAVA) for babies and children (MIB163)

    NICE has developed a medtech innovation briefing (MIB) on Serve-n with Neurally Adjusted Ventilatory Assist (NAVA) for babies and children .

  17. Predictors of acute physical risk:- What clinical and biochemical markers are the best predictors of acute physical risk for people with eating disorders?

    details Comes from guidance Eating disorders: recognition and treatment Number NG69 Date issued May 2017 Other details

  18. Premature ovarian insufficiency:- What are the main clinical manifestations of premature ovarian insufficiency and the short- and long-term impact of the most common therapeutic interventions?

    oral contraceptives are often prescribed when this might not be the best treatment in terms of quality of life and preservation of bone...

  19. Hearing loss prevalence in people who under-present for hearing loss:- What is the prevalence of hearing loss among populations who under-present for possible hearingloss?

    identified and addressed at an early stage, yet people often delay seeking treatment for up to 10 years. There are certain groups who...

  20. What is the comparative clinical and cost effectiveness of pharmacological and psychosocial interventions for anxiety disorders in autistic children and young people?

    autistic children and young people and an anxiety disorder. Pharmacological treatment should be with a selective serotonin reuptake...

  21. Modes of provision of support to healthcare professionals:- What would be the impact of dietetic telephone support to healthcare professionals to aid in the diagnosis and assessment of babies showing non-IgE-mediated food allergy symptoms in primary care and community settings?

    surgeries and health clinics, reduced need for unnecessary medications and treatment, improved health for the whole family and improved...

  22. Atezolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for early triple negative breast cancer [ID6200]

    In development Reference number: GID-TA11165 Expected publication date: TBC

  23. Social work with adults experiencing complex needs (NG216)

    This guideline covers the planning, delivery and review of social work interventions for adults who have complex needs. It promotes ways for social work professionals, other care staff and people with complex needs to work together to make decisions about care and support.

  24. HTA Lab projects

    people, or physical infrastructure may need to be built to administer treatments. These implementation costs could be very high,...

  25. Olaparib plus bevacizumab for maintenance treatment of advanced ovarian, fallopian tube or primary peritoneal cancer (TA693)

    This guidance has been updated and replaced by NICE technology appraisal guidance 946.

  26. Favezelimab–pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after anti-PD-L1 treatment [ID6393]

    In development Reference number: GID-TA11486 Expected publication date: TBC

  27. BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume (MIB50)

    NICE has developed a medtech innovation briefing (MIB) on the BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume

  28. The physical health benefits of discontinuing antipsychotic medication:- What are the short- and long-term benefits to physical health of guided medication discontinuation and/or reduction in first episode psychosis and can this be achieved without major risks?

    reducing the long-term physical health risks associated with antipsychotic treatment and improving outcomes. The programme of research...

  29. What are the causative and contributory factors underlying the persistently very low levels of reported patient satisfaction for bladder cancer?

    prolonged pattern of intrusive procedures that dominate investigation, treatment and follow-up regimens for bladder cancer may also...

  30. Early value assessment interim statement (PMG39)

    This interim statement outlines early value assessments, a new evidence-based approach designed to improve the care of people and effective use of NHS resources through quicker access to promising health technologies that address national unmet need

  31. What is the efficacy and safety of COVID-specific antiviral drugs in combination with other COVID-specific antiviral drugs or COVID-specific neutralising monoclonal antibodies in people who do not need supplemental oxygen and are within 7 days of symptom onset?

    antiviral-monoclonal antibodies C:• standard care without the combination treatment O:• effectiveness outcomes • COVID-19 related...

  32. Percutaneous interlaminar endoscopic lumbar discectomy for sciatica (IPG555)

    Evidence-based recommendations on percutaneous interlaminar endoscopic lumbar discectomy for sciatica in adults. This involves removing part of the damaged spinal disc to relieve the symptoms of sciatica.

  33. Further research in superior rectal artery embolisation for haemorrhoids should report details of patient selection, and follow-up efficacy (including symptom relief), need for subsequent treatments, quality of life and safety outcomes for at least 1 year.

    and follow-up efficacy (including symptom relief), need for subsequent treatments, quality of life and safety outcomes for at least 1...

  34. ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections (HTG602)

    Evidence-based recommendations on ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections.

  35. NICE newsletters and alerts

    Subscribe to NICE newsletters and alerts for the latest healthcare guidance, clinical updates, and evidence-based resources across health and social care.

  36. NICE newsletters and alerts

    Subscribe to NICE newsletters and alerts for the latest healthcare guidance, clinical updates, and evidence-based resources across health and social care.

  37. Falls: assessment and prevention in older people and in people 50 and over at higher risk (NG249)

    This guideline covers assessing risk of falling and interventions to prevent falls in all people aged 65 and over, and people aged 50 to 64 who are at higher risk of falls. It aims to reduce the risk and incidence of falls, and the associated distress, pain, injury, loss of confidence, loss of independence and mortality.

  38. Organisation of care:- What is the clinical and cost effectiveness of alternative approaches to organising primary care compared with usual care for people with multimorbidity?

    example, people with multimorbidity who find it difficult to manage their treatment or care or day-to-day activities, people with...

  39. Denosumab for the treatment of therapy-induced bone loss in non-metastatic prostate cancer (terminated appraisal) (TA194)

    This guidance has been updated and replaced by NICE guideline CG175.

  40. Ipilimumab for the adjuvant treatment of completely resected stage IV or high risk stage III melanoma [ID721]

    Discontinued Reference number: GID-TAG479

  41. Dupilumab for children with severe atopic dermatitis [TSID10434]

    Topic prioritisation

  42. Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer (HTG642)

    Evidence-based recommendations on Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer.

  43. Gilteritinib for maintenance treatment of FLT3-mutation-positive acute myeloid leukaemia after stem cell transplant [ID6243]

    Discontinued Reference number: GID-TA11255

  44. PeritX peritoneal catheter drainage system for vacuum-assisted drainage of treatment-resistant, recurrent malignant ascites (MTG9)

    We have moved medical technologies guidance 9 to become HealthTech guidance 282. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.